Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial

Morphotek commences MORAb-004 Phase II metastatic soft tissue sarcoma trial

Genzyme receives Refuse to File letter from FDA for LEMTRADA

Genzyme receives Refuse to File letter from FDA for LEMTRADA

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Lilly’s solanezumab Phase 3 trials on AD do not meet primary endpoints

Lilly’s solanezumab Phase 3 trials on AD do not meet primary endpoints

EMD Millipore enters definitive agreement to acquire Biochrom

EMD Millipore enters definitive agreement to acquire Biochrom

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

FDA extends action date for Pfizer’s tofacitinib NDA review

FDA extends action date for Pfizer’s tofacitinib NDA review

FSH-specific polyclonal antibody might offer more effective way to prevent osteoporosis

FSH-specific polyclonal antibody might offer more effective way to prevent osteoporosis

Mepolizumab almost halves exacerbations in severe asthma patients

Mepolizumab almost halves exacerbations in severe asthma patients

3SBio files APX001 IND application with SFDA in China

3SBio files APX001 IND application with SFDA in China

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program

PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program

University of Nevada researcher to optimize new rapid test for melioidosis

University of Nevada researcher to optimize new rapid test for melioidosis

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

Curcumin emerges as prime candidate for less expensive AD treatment

Curcumin emerges as prime candidate for less expensive AD treatment

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

Rituximab aids remission in idiopathic membranous nephropathy

Rituximab aids remission in idiopathic membranous nephropathy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.